Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | GLRA3 | O75311 | 1/20 | 0.32 |
| ▸ | GLRB | P48167 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.30 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.30 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.30 |
| ▸ | GRIK5 | Q16478 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28733623 | 0.67 | CYP1A2 (0.48) | MEN1KMT2ACYP1A2GLRA3GLRB | |
| SCHEMBL28397194 | 0.65 | CYP1A2 (0.36) | CYP1A2 | |
| SCHEMBL28783986 | 0.63 | GLRA3 (0.42) | MEN1KMT2ACYP1A2GLRA3GLRB | |
| SCHEMBL4960198 | 0.62 | — | — | |
| SCHEMBL16267376 | 0.57 | ALDH1A1 (0.46) | MEN1KMT2ACYP1A2ALDH1A1KDM4E | |
| SCHEMBL1356879 | 0.57 | CYP1A2 (0.55) | MEN1KMT2ACYP1A2ALDH1A1KDM4E | |
| SCHEMBL4353430 | 0.54 | CYP1A2 (0.59) | MEN1KMT2ACYP1A2ALDH1A1 | |
| SCHEMBL28353288 | 0.54 | CYP1A2 (0.50) | MEN1KMT2ACYP1A2ALDH1A1KDM4E | |
| SCHEMBL1582401 | 0.54 | CYP1A2 (1.00) | MEN1KMT2ACYP1A2 | |
| SCHEMBL21246419 | 0.54 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120172598-A1 | COMPOUNDS HAVING TAFIa INHIBITORY ACTIVITY | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-07-05 | — | — | US | disclosed |
| US-20050239751-A1 | Heterocyclic anti-viral compounds comprising metabolizable moieties and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2005-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172598-A1 | COMPOUNDS HAVING TAFIa INHIBITORY ACTIVITY | TAF1, TFPI, TAF1L | MEN1 3779/4885KMT2A 3997/4885CYP1A2 1100/4885 |
| US-20050239751-A1 | Heterocyclic anti-viral compounds comprising metabolizable moieties and their uses | HAVCR2, HCCS, AADAC | MEN1 4517/4885KMT2A 3996/4885CYP1A2 75/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.